Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy

    ... in lower-risk myelodysplastic syndromes (MDS). Lenalidomide (LEN) can correct anemia in 25% of MDS patients without ...

    Research Article last updated 02/21/2017 - 9:43am.

  2. Making Progress for Myelodysplastic Syndromes

    ... ), Dacogen ( decitabine ), Revlimid ( lenalidomide ). We consider transplant as a curative option for patients ...

    Article last updated 07/26/2017 - 10:25am.

  3. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine

    ... BACKGROUND: Lenalidomide and azanucleosides are commonly used to treat anemic patients ... agents (ESAs). Nonetheless, response rates to lenalidomide after azanucleosides treatment failure and their optimal ...

    Research Article last updated 12/09/2015 - 8:59am.

  4. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

    ... BACKGROUND: Lenalidomide could effectively induce red blood cell (RBC) ... syndrome (MDS) with or without 5q deletion. However whether lenalidomide ultimately improves the overall survival (OS) of lower-risk MDS ...

    Research Article last updated 11/28/2016 - 9:36am.

  5. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?

    ... March 1, 2015 Lenalidomide induces in patients with myelodysplastic syndrome (MDS) and ... 50%, respectively. It is still unclear, however, how long lenalidomide treatment should be continued and whether or not the drug could ...

    Research Article last updated 06/03/2015 - 1:21pm.

  6. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

    ... with trilineage dysplasia (AML-TD). High dose (HD) lenalidomide (50 mg) has activity as frontline therapy in elderly AML but ... included patients with RR HR-MDS or AML-TD at 2 doses of lenalidomide (15 or 50 mg) on days 1-28 of 42-day cycles. The primary endpoint ...

    Research Article last updated 11/02/2016 - 9:17am.

  7. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    ... The impact of lenalidomide treatment on long-term outcomes of patients with lower risk ... multivariate methodology to analyse the influence of lenalidomide therapy on overall survival (OS) and acute myeloblastic leukaemia ...

    Research Article last updated 07/29/2014 - 12:11pm.

  8. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International ... 239 patients were randomly assigned (2:1) to treatment with lenalidomide (n = 160) or placebo (n = 79) once per day (on 28-day cycles). The ...

    Research Article last updated 07/18/2016 - 10:30am.

  9. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    ... double-blind study assessed the efficacy and safety of lenalidomide in 205 RBC transfusion-dependent patients with IPSS ... myelodysplastic syndromes (MDS). Patients received lenalidomide 10 mg/day days 1-21 (n = 69) or 5 mg/day days 1-28 (n = 69) of ...

    Research Article last updated 07/28/2014 - 9:04am.

  10. Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.

    ... BACKGROUND: Lenalidomide is approved for the treatment of anemia with ... death. Claims were used to determine time to initiation of lenalidomide, daily dose, duration, and other MDS therapies. Transfusion status ...

    Research Article last updated 08/15/2013 - 9:50am.